Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Hold Rating at Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) in a research report released on Wednesday,Benzinga reports. The firm currently has a $107.00 target price on the stock, down from their prior target price of $140.00.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company upped their price objective on shares of Verona Pharma PLC American Depositary Share from $107.00 to $138.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. HC Wainwright increased their price target on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday, June 2nd. TD Cowen assumed coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They issued a "buy" rating and a $100.00 price target for the company. Wolfe Research assumed coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Tuesday, July 1st. They issued an "outperform" rating and a $170.00 price target for the company. Finally, Cowen assumed coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They issued a "buy" rating for the company. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Verona Pharma PLC American Depositary Share has an average rating of "Hold" and an average price target of $107.45.

Verona Pharma PLC American Depositary Share Stock Performance

Verona Pharma PLC American Depositary Share stock traded down $0.05 on Wednesday, reaching $104.81. 9,821,843 shares of the stock were exchanged, compared to its average volume of 1,603,147. The stock has a market cap of $8.92 billion, a PE ratio of -52.41 and a beta of 0.24. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. Verona Pharma PLC American Depositary Share has a twelve month low of $17.96 and a twelve month high of $104.99. The firm has a fifty day moving average price of $83.25 and a two-hundred day moving average price of $67.25.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million. Sell-side analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Insider Activity at Verona Pharma PLC American Depositary Share

In other news, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the sale, the chief financial officer directly owned 12,278,992 shares of the company's stock, valued at $139,980,508.80. This represents a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Andrew Fisher sold 80,000 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the sale, the general counsel directly owned 359,999 shares in the company, valued at $4,150,788.47. This trade represents a 18.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,965,800 shares of company stock valued at $20,056,881 over the last three months. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its stake in Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Verona Pharma PLC American Depositary Share by 14.0% during the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock worth $117,000 after purchasing an additional 225 shares in the last quarter. Townsquare Capital LLC boosted its position in shares of Verona Pharma PLC American Depositary Share by 1.9% during the fourth quarter. Townsquare Capital LLC now owns 17,958 shares of the company's stock worth $834,000 after purchasing an additional 332 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $34,000. Finally, Advisors Preferred LLC boosted its position in shares of Verona Pharma PLC American Depositary Share by 65.4% during the first quarter. Advisors Preferred LLC now owns 1,599 shares of the company's stock worth $94,000 after purchasing an additional 632 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.